Optimization and Advanced Proof-of-Concept Studies of a Listeria-vectored Multi-Antigenic Vaccine against Tuberculosis

李斯特菌载体多抗原结核疫苗的优化和高级概念验证研究

基本信息

项目摘要

PROJECT SUMMARY Tuberculosis (TB) is one of the world's most important diseases, and a safe and effective vaccine against the causative agent Mycobacterium tuberculosis (Mtb) that is more potent than the currently available only partially effective M. bovis strain Bacille Calmette-Guérin (BCG) vaccine is sorely needed. It is generally acknowledged that both an improved replacement vaccine for BCG and a potent heterologous booster vaccine are needed in the fight against TB. The purpose of this project is to optimize and conduct advanced proof-of-concept studies in small animals and non-human primates (NHP) of a second-generation heterologous multiantigenic recombinant attenuated Listeria monocytogenes-vectored vaccine against TB. Live attenuated recombinant Listeria monocytogenes (rLm) vaccines offer major advantages over other approaches to booster vaccines, including protein in adjuvant and virus-vectored vaccines, in terms of cost, ease of manufacture, immunogenicity and efficacy. In preliminary studies, we have identified an improved multi-deletional Listeria vector (Lm ΔactA ΔinlB prfA*) and demonstrated that rLm vaccines expressing four key immunoprotective Mtb proteins (rLmMtb4Ag) substantially augment protective immunity when used as a heterologous booster vaccine in a prime-boost vaccination strategy against Mtb aerosol challenge in mice and guinea pigs. Moreover, delivering the immunoprotective Mtb protein via a first generation rLm vector was more efficacious than delivering it via a recombinant viral vector or administering it with a potent adjuvant. The goal of this application is to optimize expression of an Lm-vectored vaccine expressing 4 Mtb antigens; expand its antigen repertoire to six antigens to increase its potency; and to evaluate the optimized final lead rLm vaccine candidate for safety, immunogenicity and efficacy as a standalone vaccine and as a heterologous booster vaccine to BCG-primed animals in mouse, guinea pig, and non-human primate (NHP) models of pulmonary TB. We shall accomplish this goal by: a) Optimizing the protein expression cassette of rLmMtb4Ag vaccine; systematically evaluating additional novel Mtb antigens for immunogenicity and efficacy in mice, selecting the top two antigens, and subsequently constructing a rLmMtb6Ag lead vaccine candidate; b) Conducting comprehensive proof-of-concept studies of the optimized rLmMtb6Ag lead vaccine candidate for safety, immunogenicity, and efficacy as standalone and heterologous booster vaccine in the mouse model of pulmonary TB; c) Conducting selected proof-of-concept studies of the lead rLmMtb6Ag vaccine as a standa- lone and heterologous booster vaccine for safety, immunogenicity and efficacy in a guinea pig model of pulmonary TB; and d) as Aeras requires proof-of-concept in NHP for a vaccine to enter preclinical develop- ment, evaluating the lead rLmMtb6Ag candidate as a standalone vaccine for safety, immunogenicity and efficacy in a NHP model of pulmonary TB in collaboration with Aeras, Bioqual, and Tulane National Primate Research Centre.
项目概要 结核病(TB)是世界上最重要的疾病之一,也是预防结核病的安全有效的疫苗 病原体结核分枝杆菌(Mtb)比目前仅部分有效的 迫切需要有效的牛分枝杆菌卡介苗(BCG)疫苗。这是普遍公认的 需要改进的卡介苗替代疫苗和有效的异源加强疫苗 与结核病的斗争。该项目的目的是优化并进行高级概念验证研究 在小动物和非人灵长类动物 (NHP) 中发现第二代异源多抗原 重组减毒单核细胞增多性李斯特菌载体抗结核疫苗。 重组单核细胞增生李斯特菌 (rLm) 减毒活疫苗与其他疫苗相比具有主要优势 加强疫苗的方法,包括佐剂中的蛋白质和病毒载体疫苗,在成本方面, 易于制造、免疫原性和功效。在初步研究中,我们已经确定了一种改进的 多缺失李斯特菌载体 (Lm ΔactA ΔinlB prfA*) 并证明 rLm 疫苗表达四个关键 免疫保护性 Mtb 蛋白 (rLmMtb4Ag) 用作免疫保护剂时可显着增强保护性免疫力 异源加强疫苗在小鼠和小鼠中针对 Mtb 气溶胶攻击的初免加强疫苗接种策略 豚鼠。此外,通过第一代 rLm 载体递送免疫保护性 Mtb 蛋白更有效。 比通过重组病毒载体递送或与有效佐剂一起施用更有效。 此应用的目标是优化表达 4 Mtb 的 Lm 载体疫苗的表达 抗原;将其抗原库扩展到六种抗原以增加其效力;并评估优化后的 作为独立疫苗和作为替代疫苗,其安全性、免疫原性和有效性的最终主要候选疫苗 针对小鼠、豚鼠和非人类灵长类动物 (NHP) 的 BCG 免疫动物的异源加强疫苗 肺结核模型。我们将通过以下方式实现这一目标: a) 优化蛋白质表达盒 rLmMtb4Ag 疫苗;系统地评估其他新型 Mtb 抗原的免疫原性和功效 小鼠,选择前两种抗原,随后构建 rLmMtb6Ag 候选疫苗; b) 对优化的 rLmMtb6Ag 主要候选疫苗进行全面的概念验证研究 作为独立和异源加强疫苗在小鼠模型中的安全性、免疫原性和功效 肺结核; c) 对领先的 rLmMtb6Ag 疫苗进行选定的概念验证研究作为标准 单独和异源加强疫苗在豚鼠模型中的安全性、免疫原性和有效性 肺结核; d) 由于 Aeras 需要在 NHP 中进行概念验证,以便疫苗进入临床前开发阶段 评估主要的 rLmMtb6Ag 候选药物作为独立疫苗的安全性、免疫原性和 与 Aeras、Bioqual 和 Tulane National Primate 合作,在 NHP 肺结核模型中的疗效 研究中心。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MARCUS AARON HORWITZ其他文献

MARCUS AARON HORWITZ的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MARCUS AARON HORWITZ', 18)}}的其他基金

Development of a novel TB vaccine safer and more effective than BCG based on a precisely controlled replication-limited Mycobacterium tuberculosis engineered for optimal in vivo growth and clearance
基于精确控制的复制限制结核分枝杆菌,开发出比卡介苗更安全、更有效的新型结核疫苗,该疫苗经过精心设计,可实现最佳的体内生长和清除
  • 批准号:
    10115911
  • 财政年份:
    2021
  • 资助金额:
    $ 120.07万
  • 项目类别:
Development of a novel TB vaccine safer and more effective than BCG based on a precisely controlled replication-limited Mycobacterium tuberculosis engineered for optimal in vivo growth and clearance
基于精确控制的复制限制结核分枝杆菌,开发出比卡介苗更安全、更有效的新型结核疫苗,该疫苗经过精心设计,可实现最佳的体内生长和清除
  • 批准号:
    10372028
  • 财政年份:
    2021
  • 资助金额:
    $ 120.07万
  • 项目类别:
Development of a novel TB vaccine safer and more effective than BCG based on a precisely controlled replication-limited Mycobacterium tuberculosis engineered for optimal in vivo growth and clearance
基于精确控制的复制限制结核分枝杆菌,开发出比卡介苗更安全、更有效的新型结核疫苗,该疫苗经过精心设计,可实现最佳的体内生长和清除
  • 批准号:
    10570976
  • 财政年份:
    2021
  • 资助金额:
    $ 120.07万
  • 项目类别:
Composition, Atomic Structure and Function of the Francisella Type 6 Secretion System, a Distinct Subtype Essential for Phagosomal Escape, Intracellular Replication, and Virulence
弗朗西斯菌 6 型分泌系统的组成、原子结构和功能,这是吞噬体逃逸、细胞内复制和毒力所必需的独特亚型
  • 批准号:
    10462669
  • 财政年份:
    2020
  • 资助金额:
    $ 120.07万
  • 项目类别:
Composition, Atomic Structure and Function of the Francisella Type 6 Secretion System, a Distinct Subtype Essential for Phagosomal Escape, Intracellular Replication, and Virulence
弗朗西斯菌 6 型分泌系统的组成、原子结构和功能,这是吞噬体逃逸、细胞内复制和毒力所必需的独特亚型
  • 批准号:
    10120412
  • 财政年份:
    2020
  • 资助金额:
    $ 120.07万
  • 项目类别:
Composition, Atomic Structure and Function of the Francisella Type 6 Secretion System, a Distinct Subtype Essential for Phagosomal Escape, Intracellular Replication, and Virulence
弗朗西斯菌 6 型分泌系统的组成、原子结构和功能,这是吞噬体逃逸、细胞内复制和毒力所必需的独特亚型
  • 批准号:
    10685383
  • 财政年份:
    2020
  • 资助金额:
    $ 120.07万
  • 项目类别:
Composition, Atomic Structure and Function of the Francisella Type 6 Secretion System, a Distinct Subtype Essential for Phagosomal Escape, Intracellular Replication, and Virulence
弗朗西斯菌 6 型分泌系统的组成、原子结构和功能,这是吞噬体逃逸、细胞内复制和毒力所必需的独特亚型
  • 批准号:
    10267736
  • 财政年份:
    2020
  • 资助金额:
    $ 120.07万
  • 项目类别:
Development of a Safe and Potent Vaccine Against Melioidosis using the LVS dcapB Vector Platform
使用 LVS dcapB 载体平台开发安全有效的类鼻疽疫苗
  • 批准号:
    10837445
  • 财政年份:
    2019
  • 资助金额:
    $ 120.07万
  • 项目类别:
Development of a Safe and Potent Vaccine Against Melioidosis using the LVS dcapB Vector Platform
使用 LVS dcapB 载体平台开发安全有效的类鼻疽疫苗
  • 批准号:
    10308602
  • 财政年份:
    2019
  • 资助金额:
    $ 120.07万
  • 项目类别:
Development of a Safe and Potent Vaccine Against Melioidosis using the LVS dcapB Vector Platform
使用 LVS dcapB 载体平台开发安全有效的类鼻疽疫苗
  • 批准号:
    9815937
  • 财政年份:
    2019
  • 资助金额:
    $ 120.07万
  • 项目类别:

相似海外基金

Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
  • 批准号:
    23K08213
  • 财政年份:
    2023
  • 资助金额:
    $ 120.07万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
  • 批准号:
    2881726
  • 财政年份:
    2023
  • 资助金额:
    $ 120.07万
  • 项目类别:
    Studentship
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
  • 批准号:
    10735090
  • 财政年份:
    2023
  • 资助金额:
    $ 120.07万
  • 项目类别:
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
  • 批准号:
    10722146
  • 财政年份:
    2023
  • 资助金额:
    $ 120.07万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 120.07万
  • 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
  • 批准号:
    10935776
  • 财政年份:
    2023
  • 资助金额:
    $ 120.07万
  • 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
  • 批准号:
    10935796
  • 财政年份:
    2023
  • 资助金额:
    $ 120.07万
  • 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
  • 批准号:
    10935775
  • 财政年份:
    2023
  • 资助金额:
    $ 120.07万
  • 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
  • 批准号:
    10649041
  • 财政年份:
    2023
  • 资助金额:
    $ 120.07万
  • 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
  • 批准号:
    10735964
  • 财政年份:
    2023
  • 资助金额:
    $ 120.07万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了